Effect of two sulphonylureas on the dose kinetics of glucose-induced insulin release in normal and diabetic subjects
- PMID: 111449
- DOI: 10.1530/acta.0.0910282
Effect of two sulphonylureas on the dose kinetics of glucose-induced insulin release in normal and diabetic subjects
Abstract
The effect of two second generation sulphonylureas, gliquidone and glibenclamide, on insulin secretion has been studied in the basal state and in combination with glucose infusions in normal controls, patients with mild maturity-onset diabetes, and subjects with normal glucose tolerance but low insulin response. When injected intravenously, gliquidone caused rapid elevation of plasma insulin, peaking at 5 min in all groups, while glibenclamide induced a slow rise in insulin. Insulin response was somewhat smaller than normal in diabetics and low insulin responders. In all groups, 25 micrograms/kg glibenclamide and 200 micrograms/kg gliquidone were equipotent in generating an insulin response at the basal state. Equipotent amounts of sulphonylureas were combined with glucose in fusions at three different dose levels. The glucose-insulin dose relationships, established by giving glucose alone, demonstrated curves that were flatter, and shifted to the right of the control in diabetics and low insulin responders, the changes being more marked in the former group. Addition of sulphonylurea induced a left shift in the dose-response relationships in controls and low insulin responders; under these conditions the effect of glibenclamide was more pronounced than that of gliquidone. The dose-response relation for glucose-induced insulin release was completely normalized in low responders when sulphonylureas were added. In the group of mild diabetics, insulin response to glucose was enhanced by sulphonylureas only to a modest extent, the dose-response curves remaining grossly abnormal.
Similar articles
-
[Effect of gliquidone and glibenclamide following oral administration].MMW Munch Med Wochenschr. 1975 Sep 5;117(36):1423-4. MMW Munch Med Wochenschr. 1975. PMID: 809687 German.
-
[The influence of various sulphonylurea derivatives on the oral glucose-tolerance tests in healthy subjects and obese and maturity-onset diabetics (author's transl)].Dtsch Med Wochenschr. 1974 Mar 1;99(9):385-8. doi: 10.1055/s-0028-1107768. Dtsch Med Wochenschr. 1974. PMID: 4208186 Clinical Trial. German. No abstract available.
-
Desensitization of sulphonylurea- and nutrient-induced insulin secretion following prolonged treatment with glibenclamide.Eur J Pharmacol. 2000 Nov 24;408(3):327-33. doi: 10.1016/s0014-2999(00)00782-2. Eur J Pharmacol. 2000. PMID: 11090651
-
Is there a concentration-effect relationship for sulphonylureas?Clin Pharmacokinet. 1998 Mar;34(3):181-8. doi: 10.2165/00003088-199834030-00001. Clin Pharmacokinet. 1998. PMID: 9533980 Review.
-
The role of sulphonylureas in the management of type 2 diabetes mellitus.Drugs. 2004;64(12):1339-58. doi: 10.2165/00003495-200464120-00006. Drugs. 2004. PMID: 15200348 Review.
Cited by
-
Comparative dose-related time-action profiles of glibenclamide and a new non-sulphonylurea drug, AG-EE 623 ZW, during euglycaemic clamp in healthy subjects.Diabetologia. 1994 Jul;37(7):703-7. doi: 10.1007/BF00417695. Diabetologia. 1994. PMID: 7958542 Clinical Trial.
-
Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs.Clin Pharmacokinet. 1981 May-Jun;6(3):215-41. doi: 10.2165/00003088-198106030-00003. Clin Pharmacokinet. 1981. PMID: 7016385 Review. No abstract available.
-
The influence of glipizide on early insulin release and glucose disposal before and after dietary regulation in diabetic patients with different degrees of hyperglycaemia.Eur J Clin Pharmacol. 1988;35(1):31-7. doi: 10.1007/BF00555504. Eur J Clin Pharmacol. 1988. PMID: 3065086
-
Oral hypoglycaemic agents. An update.Drugs. 1984 Jul;28(1):62-78. doi: 10.2165/00003495-198428010-00004. Drugs. 1984. PMID: 6378583 Review.
-
Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.Clin Pharmacokinet. 1989 Feb;16(2):100-28. doi: 10.2165/00003088-198916020-00004. Clin Pharmacokinet. 1989. PMID: 2656043 Review.